Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome subunit beta type-4 (PSMB4) is a protein encoded by the PSMB4 gene, incorporated into the 20S core of the proteasome complex. As one of 28 subunits, it is critical for the assembly and stability of the proteasome, a multicatalytic proteinase complex responsible for ATP/ubiquitin-dependent degradation of damaged or regulatory proteins in a non-lysosomal pathway. While PSMB4 itself is non-catalytic, its role in forming the proteolytic chamber is essential for the complex's function. Dysregulation of the proteasome system, including PSMB4, is implicated in various pathological states, including cancer, neurodegenerative diseases, cardiac conditions, and inflammation. Therapeutically, the proteasome serves as a validated drug target, particularly in oncology, and circulating proteasome components are emerging as potential disease biomarkers
Proteasome inhibition (blocking proteolytic activity disrupts protein degradation, leading to cell cycle arrest and apoptosis, especially in cancer cells)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome subunit beta type-4 (PSMB4).